Alpelisib key points.PNG (88.5 kB)

Alpelisib: First Global Approval

Download (88.5 kB)
online resource
posted on 03.07.2019 by Anthony Markham
Compliance with Ethical Standards

Disclosure The preparation of this review was not supported by any external funding.

Conflicts of interest  A. Markham, a contracted employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

Additional information about this Adis Insight Report can be found here

Abstract

Alpelisib (Piqray™) - an orally available phosphatidylinositol 3-kinase (PI3K) inhibitor with specific activity against PI3K alpha (PI3Kα) - is being developed by Novartis for the treatment of breast cancer. Alpelisib has demonstrated efficacy in combination with fulvestrant as treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer in patients with a PIK3CA mutation and was recently approved for this indication in the USA. This article summarizes the milestones in the development of alpelisib leading to this first approval.

© Springer Nature Switzerland AG 2019

History

Exports

Read the peer-reviewed publication

Logo branding

Categories

Exports